Susan E. Bates

Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.

W. Wilson, T. Fojo, S. Bates, 1998, Blood.

Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.

A. Gazdar, S. Bates, A. Fojo, 1991, The Journal of clinical endocrinology and metabolism.

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

P. Choyke, T. Fojo, S. Bates, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical reversal of multidrug resistance.

W. Wilson, A. Monks, C. Hose, 1996, Stem cells.

Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.

W. Wilson, S. Steinberg, R. Wittes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines.

S. Bates, A. Fojo, J. Trepel, 1992, Journal of the National Cancer Institute.

Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials

Mengxi Zhou, Susan E. Bates, Celine Yeh, 2023, Breast cancer research and treatment.

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment

S. Steinberg, P. Choyke, M. Burotto, 2016, Breast Cancer Research and Treatment.

Reversal of multidrug resistance.

W. Wilson, A. Fojo, Z. Zhan, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.